Combinatorial immunotherapy: PD-1 may not be LAG-ing behind any more

Meghan E. Turnis, Alan J. Korma, Charles G. Drake, Dario A A Vignali

Research output: Contribution to journalArticlepeer-review

Abstract

Cancer immunotherapy attempts to harness the immune system by breaking tolerance and generating a robust anticancer response. we have recently demonstrated a synergistic enhancement in tumor clearance following therapeutic, dual PD-1 and LAG-3 blockade. here, we discuss the implications of these fndings in the context of future combinatorial immunotherapeutic approaches.

Original languageEnglish (US)
Pages (from-to)1172-1174
Number of pages3
JournalOncoImmunology
Volume1
Issue number7
DOIs
StatePublished - 2012

Keywords

  • Cancer
  • CD152
  • CD223
  • CD279
  • CTLA-4
  • Immunotherapy
  • Ipilimumab
  • LAG-3
  • Lymphocyte
  • MDX-1106
  • PD-1
  • Synergy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'Combinatorial immunotherapy: PD-1 may not be LAG-ing behind any more'. Together they form a unique fingerprint.

Cite this